💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Risankizumab

CHEMBL3990029 Phase 4 معتمد Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Risankizumab is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor and preventing downstream Th17 cell differentiation and pro-inflammatory cytokine production. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn's disease, and moderate-to-severe ulcerative colitis.

المجالات العلاجية

Asthma Inflammatory Bowel Disease Psoriasis Atopic Dermatitis

آلية العمل

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Risankizumab is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor and preventing downstream Th17 cell differentiation and pro-inflammatory cytokine production. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn's disease, and moderate-to-severe ulcerative colitis.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Risankizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3990029. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.